12th Annual Conference
for the
Diagnosis and Treatment of
Neuroendocrine Tumor Disease

11-13 March 2015, Barcelona, Spain
Welcome to Barcelona

Programme Introduction

On behalf of the ENETS Society and the ENETS Executive Committee it is our pleasure and privilege to welcome you to the 12th Annual ENETS Conference in Barcelona.

The scientific organising committee took great efforts to develop a scientific programme that offers a broad spectrum of expertise and a well-laid-out structure. The conference will begin this year with the now very popular Post Graduate Course on Wednesday, March 11th. On Thursday following the “sold out” Meet the Professor Sessions’ we begin our main programme. I would like to point out that our plenary sessions deal with Cancer Progression and Resistance as well as Tumor Immunology and Local Environment. These topics are critical to cancer biology and we will learn lessons from other cancers especially melanoma (a cousin of NET). The other plenary sessions including Clinical Use of GPCR Advances in Nuclear Medicine, Pulmonary NETs should be highly stimulating.

Our multi-national and multi-disciplinary speakers will be covering a wide spectrum of topics ranging from MEN-1, Symptom Control in NETs and its case presentations through to the Key Note Lecture on Medullary Thyroid Carcinoma and followed by sessions encompassing Familial NETs from Bench to Bedside as well as Mixed Adeno-NET and thus avid panel discussions await you here. We are looking forward to a rigorous discussion on Biomarkers Outside Chromogranin and Beyond as well as Metastatic NET of Unknown Primary.

We would also like to emphasize the importance of this year’s Nurses Symposium. We are delighted that the NET Nurses are now affiliated with ENETS. The Nurses Symposium programme is most worthwhile as it discusses Quality of Life Survey Data and will end with the discussions including Nutrition. The increasing involvement and support of Nurses within ENETS is a priority during my term as chairman.

Another important advance for the Society is the announcement this year of our many new grants & awards. We are committed to stimulating young investigators, funding research programmes and enabling interaction of investigators from all around the world. We have 13 travel grant winners, 14 oral abstract winners from over 200 abstracts received. We are proud to award the recipients for the new Centres of Excellence, Young Investigator Grant, CoE Training Grant, Hakan Ahlman Award as well as the Translational Medicine in GEP-NET Disease Grant. The ENETS reviewing committees took into consideration all aspects of the works that were submitted by many strong candidates. The new grants along with the Poster Awards and the newly founded Centres of Excellence will be awarded during the Grants and Awards Ceremony on Friday, 13 March 2015.
Welcome to Barcelona

We would like to introduce you to the newly founded CoE Excellence Academy Fellowship Project. This project seeks to support the most promising Young Investigators ‘Shooting/Rising Star’ in the field of neuroendocrine tumors, which should support mainly scientific cooperative projects and improvement of networking between the Centre of Excellence (CoE) within ENETS and beyond.

Special mention has to be made of our life-time achievement award dedication to Dr. Robert Jensen. Robert has been a colossus in the NET field, a dinosaur who still roars in a benevolent and collegiate manner. You will all be aware of his work especially related to gastrinomas and he is a worthy recipient of this unanimously voted honour.

Overall this year’s conference programme has been reviewed by an international committee and has been awarded 16 European CME credits by the European Union of Medical Specialists (UEMS) and the European Accreditation Council for CME (EACCME®). Please be sure to have your name badge scanned before entering the morning and afternoon lectures so that your attendance certificate following the conference reflects the time spent in each session.

We hope that this exciting conference will foster once more the exchange of NET expertise between the people from different countries around the World in order to help better understand NET and we will try and make this as fun as possible.

To our sponsors and exhibitors and valued participants and patient advocates from previous ENETS conferences, I extend a warm welcome back and thank you for continuing to support ENETS.

Our aim was to prepare a high level conference and initiate an open and friendly atmosphere for communication among experts and non-experts coming from all areas of the world and we hope we fulfill these expectations.

Martyn Caplin, London, United Kingdom
Chairman, European Neuroendocrine Tumor Society (ENETS)
**ENETS Office Location & Opening Hours**
The ENETS Office is located in Room 134 on the first floor of the CCIB conference venue. The Office will be open as follows:

- 11 March 2015: 7:00 – 18:30
- 12 March 2015: 7:00 – 18:00
- 13 March 2015: 7:00 – 17:00

**Business Services, printing boarding passes, etc.**
The ENETS Conference business center is located in Room 118 of the CCIB, on the first floor. The business center has the same opening hours as the ENETS Office. Laptops and printing services, including for that of boarding passes or any other material, are available here.

**Registration hours**
The registration desk area, which is located on the ground floor of the CCIB, will be open as follows:

- 11 March 2015: 7:00 – 18:30
- 12 March 2015: 7:00 – 18:00
- 13 March 2015: 7:00 – 17:00

**Name badges and barcodes scan for acquiring CME points**
Every ENETS conference participant will receive a name badge with a barcode. The badge must be worn at all times in the conference venue. Every badge will be scanned BOTH before the morning and afternoon lectures in the conference plenary room.

Please be aware that you will only receive your CME credits if you have been present in the conference lectures and your badge has been scanned before the morning AND the afternoon session. In order to have all your achieved CME credits indicated on your certificate, please print your certificate on your last day just before you leave the conference.

The distribution of the CME points is as follows:
- 6 CME points are issued on 11 March for the PG course only
- 5 CME points for the regular full programme on 12 March and
- 5 CME points for the regular full programme on 13 March

In order to receive the full amount of 10 CME points for 12 and 13 March, you must be present in the sessions you attend, and MUST make sure your badge is scanned upon entering the sessions BOTH in the morning and afternoon. If you lose your badge, please go to the registration desk to receive a new one.

Please note that we do NOT have a standard conference app this year. Stay tuned for the upcoming more advanced, redesigned app in next year's conference.

**Meet the Professor Sessions**
These sessions must have been pre-registered for and attendance is limited. Registered participants must be present at the session room no later than 7:20. No-show slots will be given to interested delegates who were assigned to a waiting list. If you signed up on the waiting list, you should be at the session room by 7:20 and must have the € 50 in cash for immediate payment.
Certificates of attendance and accreditation
Every conference delegate will receive a certificate of attendance and accreditation. This certificate is granted under the auspices of the UEMS accreditation authorities in Brussels. The accreditation shown on the certificate is based on when the participant was present in the scientific sessions, and therefore, every participant should be sure to have his or her name badge scanned upon entering both the morning and afternoon lectures. Following the conference, participants should visit any of the certificate terminals / evaluation desks situated in the foyer on ground floor of the conference area so as to redeem their CME points and print out their attendance/accreditation certificates.

You will need to scan your badge and fill out the evaluation form provided to print your certificate. A detailed instruction sheet is available at the desk as well as a hostess to help with the procedure.

Lost & Found / Cloakroom
Lost & Found items can be brought to and retrieved at the registration desk at the ground floor of the CCIB. The cloakroom is located on the ground floor, adjacent the main entrance. Opening hours are the same as that of the registration desk. It is also open for the Welcome Reception and the industry symposia.

Congress bag
Every participant will receive a congress bag at the ENETS 2015 conference, available for pick-up at the registration area. The following items should be included in each bag: conference programme, mini-programme, abstract booklet, sponsor booklet, memory stick, post-it notes, ballpoint pen, highlighter, block of paper, and a cotton shopping bag with the ENETS logo.

Speakers Preview Room
Room 119 on the first floor of the CCIB has been designated for conference speakers to socialize and also to upload and preview their presentations. Please be aware, too, that all conference speakers must have uploaded their presentations at least one hour before expected on stage.

Satellite Symposium
The ENETS 2015 Annual Conference includes three symposia organized by the platinum, gold and silver sponsors. Entry to these symposia is free of charge. The schedule is as follows:

Satellite Symposium I: Thursday, 12 March, 12:45 – 14:15, Room 112, First Floor, Level P1
Satellite Symposium II: Thursday, 12 March, 18:00 – 19:30, Room 112, First Floor, Level P1
Satellite Symposium III: Friday, 13 March, 13:00 – 14:15, Room 112, First Floor, Level P1

ENETS General Assembly
Every ENETS member is welcome to attend the Society’s annual General Assembly meeting. Only ENETS members are allowed entry to the General Assembly meeting and only those members who have paid all their membership fees up to 2015 are entitled to vote on any agenda items. The General Assembly meeting will be held on Thursday, 12 March at 17:00 in Room 111, First Floor, Level P1.

Internet / WiFi access
Wireless internet access will be available in most areas. The SSID of the network will be “ENETS 2015”, and the password will be “Barcelona”.

General Information
Ground floor

Exhibitors:
01 = Ipsen
02 = Novartis
03 = Sirtex
04 = ADACAP
05 = Pfizer
06 = Novartis
1 = INCA
Dr. Robert T. Jensen

Dr. Robert T. Jensen is currently Chief, Cell Biology Section, in the Digestive Diseases Branch, NIDDK at the NIH, USA. He is known both nationally and internationally for both his clinical and basic science studies.

Throughout his career he has been productive in both areas producing more than 800 papers. His clinical studies have primarily used gastrinomas (Zollinger-Ellison-syndrome) as a model to study different aspects of functional pNETs including treatment of the hormone-excess state, surgery, tumor localization, natural history, treatment of advanced disease and the role of MEN1 in a subset of patients.

Many of these clinical studies were the first prospective studies performed in this area and have had a widespread effect on treatment/management of these patients. His basic science studies have involved the pharmacology and cell biology of gastrointestinal hormones. He has trained more than 90 postdoctoral fellows many of whom are now well established in related fields in the USA, Europe and Asia.

Life Achievement Award

Executive Committee & Advisory Board Members

The members of the ENETS Executive Committee are:

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martyn Caplin</td>
<td>GBR</td>
</tr>
<tr>
<td>Kjell Öberg</td>
<td>SWE</td>
</tr>
<tr>
<td>Massimo Falconi</td>
<td>ITA</td>
</tr>
<tr>
<td>Bertram Wiedenmann</td>
<td>GER</td>
</tr>
<tr>
<td>Aurel Perren</td>
<td>SUI</td>
</tr>
<tr>
<td>Rocio Garcia-Carbonero</td>
<td>ESP</td>
</tr>
<tr>
<td>Reza Kianmanesh</td>
<td>FRA</td>
</tr>
<tr>
<td>Dermot O’Toole</td>
<td>IRL</td>
</tr>
<tr>
<td>Marianne Pavel</td>
<td>GER</td>
</tr>
</tbody>
</table>

The ENETS Advisory Board was established in 2008 to assist the ENETS Executive Committee in research matters and the Society’s organizational structure. Members hold office for three years, and are selected for their advanced standing in the field of NET research.

The elections for the Advisory Board will take place on Thursday, March 12th during the General Assembly for ENETS members.

The members of the ENETS Advisory Board are:

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Detlef Bartsch</td>
<td>GER</td>
</tr>
<tr>
<td>Eric Baudin</td>
<td>FRA</td>
</tr>
<tr>
<td>Jaume Capdevila</td>
<td>ESP</td>
</tr>
<tr>
<td>Frederico Costa</td>
<td>BRA</td>
</tr>
<tr>
<td>Jaroslaw Cwikla</td>
<td>POL</td>
</tr>
<tr>
<td>Wouter de Herder</td>
<td>NED</td>
</tr>
<tr>
<td>Gianfranco Delle Fave</td>
<td>ITA</td>
</tr>
<tr>
<td>Barbro Eriksson</td>
<td>SWE</td>
</tr>
<tr>
<td>Piero Ferolla</td>
<td>ITA</td>
</tr>
<tr>
<td>Diego Ferone</td>
<td>ITA</td>
</tr>
<tr>
<td>David J Gross</td>
<td>ISR</td>
</tr>
<tr>
<td>Ashley Grossman</td>
<td>GBR</td>
</tr>
<tr>
<td>Tetsuide Ito</td>
<td>JAP</td>
</tr>
<tr>
<td>Pelepu Jagannath</td>
<td>IND</td>
</tr>
<tr>
<td>Robert Jensen</td>
<td>USA</td>
</tr>
<tr>
<td>Gregory Kaltas</td>
<td>GRE</td>
</tr>
<tr>
<td>Fahrettin Kelestimur</td>
<td>TUR</td>
</tr>
<tr>
<td>Ulrich Knigge</td>
<td>DEN</td>
</tr>
<tr>
<td>Beata Kos Kudla</td>
<td>POL</td>
</tr>
<tr>
<td>Matthew Kulke</td>
<td>USA</td>
</tr>
<tr>
<td>Dik Kwekkeboom</td>
<td>NED</td>
</tr>
<tr>
<td>Emmanuel Mitry</td>
<td>FRA</td>
</tr>
<tr>
<td>Bruno Niederle</td>
<td>AUT</td>
</tr>
<tr>
<td>Juan O’Connor</td>
<td>ARG</td>
</tr>
<tr>
<td>Ulrich-Frank Pape</td>
<td>GER</td>
</tr>
<tr>
<td>John Ramage</td>
<td>GBR</td>
</tr>
<tr>
<td>Eric Raymond</td>
<td>FRA</td>
</tr>
<tr>
<td>Guido Rindi</td>
<td>ITA</td>
</tr>
<tr>
<td>Andrea Rockall</td>
<td>GBR</td>
</tr>
<tr>
<td>Philippe Ruszniewski</td>
<td>FRA</td>
</tr>
<tr>
<td>Ramon Salazar</td>
<td>ESP</td>
</tr>
<tr>
<td>Aldo Scarpa</td>
<td>ITA</td>
</tr>
<tr>
<td>Eva Sedlackova</td>
<td>CZE</td>
</tr>
<tr>
<td>Halfdan Sorbye</td>
<td>NOR</td>
</tr>
<tr>
<td>Anders Sundin</td>
<td>SWE</td>
</tr>
<tr>
<td>Rajesh Thakker</td>
<td>GBR</td>
</tr>
<tr>
<td>Eric Van Cutsem</td>
<td>BEL</td>
</tr>
<tr>
<td>Wolfgang Weber</td>
<td>GER</td>
</tr>
<tr>
<td>James Yao</td>
<td>USA</td>
</tr>
<tr>
<td>Zeng Zheng-Pei</td>
<td>CHN</td>
</tr>
</tbody>
</table>
Welcome to the 5th Annual ENETS Postgraduate Course. We hope that this year’s course will again be informative and stimulating.

The PG Course topics will cover overviews and summary of advances in: Epidemiology, utility of Ki67, Somatostatin Analogues, Surgery for Small Intestinal NET, Case Presentation, Carcinoid Heart Disease, Molecular Targeted Therapies for Pancreatic NET, P-NET Case Presentation, Nutritional Issues in NET, Endoscopic versus Surgical Therapy for Rectal NET, Management of Paraganglioma and Phaeochromocytoma and new topic to ENETS Merkel Cell Tumours.

This course forms part of our continuing medical education (CME) strategy and you will be able to test yourself on modules, which are being developed and available on our ENETS website www.enets.org.

We are very lucky to have such well-known and high quality speakers for the postgraduate course and we hope you will take the opportunity to ask questions and meet the speakers during the breaks.

Best wishes,
MARTYN CAPLIN & ROCIO GARCIA-CARBONERO

---

### Biographies

#### Professor Jürgen C. Becker, MD, PhD

Jürgen Becker received his medical degree from the Medical School Hannover for his work on the immune regulatory capacity of natural killer cells on the adaptive immune system. Thereafter, he first trained in Dermatology at the University of Würzburg, in Tumor Immunology at the Scripps Research Institute, La Jolla, and the Danish Cancer Society, Copenhagen. For his characterization of the impact of therapeutic interventions on the adaptive immune responses against melanoma in preclinical models he received the PhD in Immunology. Since 2003 he is full professor for Dermato-Oncology in Würzburg. He coordinated a Clinical Research Group focusing on the tumor microenvironment. In 2010, he was appointed as director of General Dermatology at the Medical University of Graz. Here he successfully attracted the FP7 EU-project IMMOMEC, which he coordinates, and became deputy speaker of the graduate training program DK-Molin. In September 2014, he joined the German Cancer Consortium (DKTK) and is now head of the Institute for Translation Skin Cancer Research (TSCR) within at the University Hospital Essen. His research interests focus on the reciprocal effects of tumor and host cells, and more recently external factors such as bacteria (e.g. in cutaneous squamous cell carcinoma; CSCC) and viruses (e.g. in Merkel cell carcinoma; MCC) as well as the identification of prognostic and predictive biomarkers (e.g. for immune modulating therapy in melanoma).

#### Professor Martyn Caplin, BSc Hons, DM, FRCP

Professor Martyn Caplin, is Professor of Gastroenterology & GI Neuroendocrinology at the Royal Free Hospital and University College London. He leads The Royal Free Hospital’s “European Neuroendocrine Tumour Society’s Centre of Excellence”. He leads both scientific and clinical research programmes into neuroendocrine tumours. In 2014 he was elected Chairman of the European Neuroendocrine Tumour Society. He has recently received a Lifetime Achievement Award from the UK & Ireland Neuroendocrine Tumour Society (UKI NETS) in recognition of his clinical leadership and research in the field of NETs. He is a founder and past-chairman of the UK & Ireland Neuroendocrine Tumour Society. 2006-2014 he was a member of the National Cancer Research Institute (NCRI) upper-G.I. Cancer committee and he is immediate past chairman of the NCRI Neuroendocrine Tumour group. He has published over one hundred and fifty peer review papers, written multiple book chapters and co-authored two books. He regularly lectures both nationally and internationally. Between 2006-12 he was the clinical lead for “NHS Evidence” for Gastroenterology and Liver diseases (under the auspices of NICE) chairing annual evidence updates into gastrointestinal and liver disorders.

Dr. Louis de Mestier serves as clinical assistant in the Department of Hepato-Gastroenterology and Digestive Oncology led by Prof. G Cadiot and Prof. P Kianmanesh at the Robert-Debré University Hospital, Reims, France. He is specialized in digestive oncology and especially in the clinical management of patients with NETs. He has performed a basic science fellowship in the NET center of excellence at Beaujon Hospital, France, under the direction of Prof. A Couvelard and Prof. P Ruszniewski. His main areas of clinical and basic research include pancreatic and intestinal NETs, and genetic syndromes such as VHL, MEN1 and familial midgut carcinoids. He has published several peer-reviewed papers and book chapters in the field of NETs. He is member of the French NET network (GTE), for which he has led several research studies including familial midgut carcinoids.

Professor Rocio Garcia-Carbonero

Rocio Garcia-Carbonero is a medical oncologist with particular expertise in gastrointestinal neoplasias. She coordinates the Gastrointestinal (GI) Tumor Unit at the Hospital Universitario Doce de Octubre in Madrid, and is also associate professor at University. She is actively involved in clinical and translational research, and is a member of the Scientific Advisory Group (SAG) for Oncology at the European Medicines Agency (EMA) since 2008. Her major areas of research interest are the development of new drugs or therapeutic strategies in the field of GI tumors, particularly NETs and colorectal cancer, and the development of biomarkers of diagnostic or therapeutic interest in this field. She has published more than 80 papers in peer-reviewed journals, as well as many book chapters, and is also an active member of various scientific societies (ASCO, ESMO, ENETS, SEOM) and collaborative groups (EROTC, GETNE, TTT). Dr Garcia-Carbonero is a member of the Executive Committee of the Spanish Society of Medical Oncology (SEOM) and deputy-Chair of the ESMO e-learning and Continued Medical Education Working Group (ECMWG). She is a national leader in the field of neuroendocrine tumors, being the current president of the Spanish cooperative group in NETs (GETNE), the main national cooperative group in the field of neuroendocrine tumors, and member of the Executive Committee of the European Society of Neuroendocrine Tumors (ENETS).
Biographies Postgraduate Course

Professor Massimo Falconi, MD
Dr. Massimo Falconi is currently Full Professor of Surgery and Chairman of the Pancreatic Unit at the University Vita e Salute, San Raffaele Hospital IRCCS, in Milan, Italy. He studied medicine at the University of Verona, specializing in general surgery, gastroenterology and endoscopy. He has participated in international medical research projects in such diverse places as Germany, Spain, Ecuador and Japan. A member of many medical societies, including IAP, EPC, ENETS and I and EAHIPBA.

Professor Diego Ferone, MD, PhD
Dr. Ferone is Professor of Endocrinology and Endocrine Oncology at the Department of Internal Medicine & Medical Specialties, section of Endocrinology, at the University of Genova, senior member of the Italian Endocrine Society (where he also served as Treasurer), past-secretary of the Italian Society of Andrology and Sexual Medicine, member of the Advisory Board of the European Neuroendocrine Tumor Society, of the ExCo of the European Neuroendocrine Association, and of several Editorial Boards, Associate Editor for the Journal of Endocrinological Investigation and for Clinical Endocrinology. Dr. Ferone, after the degree in Medicine and the postgraduate degree in Endocrinology and Metabolic Diseases at the Federico II University of Naples (I), received the PhD degree in Neuroendocrinology in Rotterdam (NL) at the Erasmus University. He has been awarded by the Italian Society of Endocrinology as best young investigator in 1999, and best senior scientist in 2011, he also received an award as best Italian researcher in the field of Neuroendocrine Tumors and MEN in 2010. Dr. Ferone has been constantly involved in studies on the physiopathology and treatment of pituitary and neuroendocrine tumors, and is author of more than 190 articles and 30 chapters of book (total impact factor 530; h-index 44), and presented more than 400 lectures in international and national meetings.

Professor Ashley Grossman, MD, BA, BSc, FRCP, FMedSci
Ashley Grossman is Professor of Endocrinology at the University of Oxford, Consultant Physician in the Oxford Centre for Diabetes, Endocrinology and Metabolism, and is a fellow of Green-Templeton College, Oxford. Following a degree in Psychology and Social Anthropology, he then entered University College London where he graduated initially with a degree in Anatomy, and then in Medicine. He eventually took up a post in the Dept. of Endocrinology at St Bartholomew’s Hospital, becoming Professor of Neuroendocrinology in 1993. He was appointed Fellow of the Academy of Medical Sciences in 1999. He has more than 190 articles and currently reviews articles for the following publications: Annals of Oncology, British Journal of Surgery, Cochrane, Gut, Lancet, Neuroendocrinology, Nutrition, Pancreas, Pancreatology, Journal of Endocrinological Investigation (JEI), Journal Of The Pancreas (JOP), Surgery, Annals of Surgery. Dr. Falconi serves as Associate Editor for the section of the pancreas and neuroendocrine tumors for Digestive and Liver Disease, official journal of the Italian and French Gastroenterological societies. He is also editorial member of the following journals: World Journal of Gastroenterology, subject Area Editor of The International Journal of Biological Markers and of International Journal of Endocrine Oncology. He has an impact factor calculated on the basis of JCR 2013 of more than 1,400 and his h index on Scopus is 58.

Professor Reza Kianmanesh, MD, PhD
Reza Kianmanesh studied medicine in Paris 7 Diderot University, Paris, France. He got his PhD in Cancer Gene Therapy in NY, USA (Pr RG Crystal), and became Assistant-Professor in HBP surgery in Prof. Jacques Belghiti’s Team and specialized himself in the treatment of digestive NETs after working with Prof. Philippe Ruszniewski in Bichat Hospital, Paris, France. He is a member of ENETS Advisory Board since 2007 and was elected as an Executive Committee member in 2014. Full professor in digestive and oncological surgery (Paris 7 University), he is, since 2011, Chief of the department of general, digestive and endocrine surgery in R. Debré University Hospital, in Reims, France. HPB surgery, LT, peritoneal carcinomatosis cytoreductive surgery and multidisciplinary treatment of digestive NETs represent his preference domains of competence. Kianmanesh collaborates actively with Prof. Guillaume Cadot, in Reims hospital-university and inside the French NET regional and national networks.

Professor Dermot O’Toole, MD, FRCPI
Dermot O’Toole is Professor of Gastroenterology and Clinical Medicine at Trinity College and is a Consultant Gastroenterologist in St James’s Hospital. He graduated from Trinity College Dublin where he also obtained his MD and also has degrees awarded from the University of Paris (Paris VII). Professor O’Toole leads the National group in neuroendocrine tumours (NET) and plays a lead role in the endoscopic treatment of early neoplasia of upper and lower gastrointestinal cancers. He also serves on the Executive Committee of the European Neuroendocrine Tumor Society (ENETS). He has been principal investigator and/or coordinator in many national and international research activities in GI oncology and neuroendocrine tumours including studies involving EUS, chemoembolisation, biotherapy and angiogenesis. He is a Fellow of the Royal College of Physicians of Ireland as well as numerous professional bodies in Europe and North America and has served as advisor on many patient advocacy groups.

Professor Marianne Pavel, MD
Professor Marianne Pavel is a Senior Physician and Leader of the Section for Neuroendocrine Tumors in the Department of Hepatology and Gastroenterology at the Charité University Hospital, Campus Virchow- Klinikum in Berlin, Germany. She received her medical degree in 1992 from the Georg-August University in Göttingen, Germany. In 1994 she completed her residency at the Friedrich-Alexander University of Erlangen-Nürnberg, Germany. Board certified as a specialist in internal medicine in 2000 and endocrinology and diabetes in 2001, she was appointed as Vice Head of the Department of Endocrinology and Metabolism at the Friedrich-Alexander University in 2001. At the University she built up a Center for NET disease in Germany and co-founded the first support group for NET patients. In 2006 she was appointed Dr. Pavel to the Executive Committee of the European Neuroendocrine Tumor Society (ENETS). She has been principal investigator and/or coordinator in many national and international research activities in GI oncology and neuroendocrine tumours including studies involving EUS, chemoembolisation, biotherapy and angiogenesis. He is a Fellow of the Royal College of Physicians of Ireland as well as numerous professional bodies in Europe and North America and has served as advisor on many patient advocacy groups.

Professor Marianne Pavel, MD
Professor Marianne Pavel is a Senior Physician and Leader of the Section for Neuroendocrine Tumors in the Department of Hepatology and Gastroenterology at the Charité University Hospital, Campus Virchow- Klinikum in Berlin, Germany. She received her medical degree in 1992 from the Georg-August University in Göttingen, Germany. In 1994 she completed her residency at the Friedrich-Alexander University of Erlangen-Nürnberg, Germany. Board certified as a specialist in internal medicine in 2000 and endocrinology and diabetes in 2001, she was appointed as Vice Head of the Department of Endocrinology and Metabolism at the Friedrich-Alexander University in 2001. At the University she built up a Center for NET disease in Germany and co-founded the first support group for NET patients. In 2006 she was appointed to the Academic Council at the Friedrich-Alexander University, and in 2007 she took her current position as an Assistant Director at the Charité University Hospital. She has conducted numerous clinical trials in endocrinology and gastroenterology with a strong focus on NET protocols and novel therapeutic approaches. In 2009, under her guidance, the NET Center at the Charité University was certified as the first ENETS Center of Excellence. She serves on the ENETS Executive Committee.
Biographies

Postgraduate Course

Professor Aurel Perren, MD
Aurel Perren is a Professor of Pathology at the University Bern. His research focus is the histopathological and genetic analysis of familial and sporadic NET with a special interest in pancreatic NET. He was involved in the WHO classification of endocrine tumors 2004 and since the first Frascati meeting in 2005, Aurel Perren is regularly involved in European Neuroendocrine Tumor Society (ENETS) activities. He is currently Scientific Secretary of the ENETS Executive Committee. He brings in the viewpoint of pathology and genetics in interdisciplinary discussions. He has published in numerous scientific journals and is member of the editorial boards of Endocrine pathology, Pathobiology, Virchows archives and Endocrine related cancer.

Professor Karl Stangl, MD
Karl Stangl, MD is Professor of Internal Medicine at Charité Medical Center, Humboldt University Berlin. He is Head of the Cardiac Catheterization Laboratories, Charité Hospital, Campus Mitte. He has performed over 10,000 procedures including more than 1000 transcatheter aortic valve implantations and MitraClip procedures. Dr. Stangl has co-authored more than 200 publications and he now helps to shape the field of catheter-based therapies of the pulmonary and tricuspid valve. Dr. Stangl was previously attending physician at the Technical University Hospital Munich, where he also had completed a fellowship in Cardiology and his internship and residency in Internal Medicine.

Professor Philippe Ruszniewski, MD
Professor Philippe Ruszniewski is currently Head of the Department of Gastroenterology-Pancreatology in Beaujon’s Hospital, Clichy, France, and Professor of Gastroenterology at University Paris 7, Denis-Diderot. He is also responsible for the Pole of Liver, Digestive and Pancreatic Diseases located in Beaujon, Bichat and Louis-Mourier Hospitals. His main areas of interest are digestive neuroendocrine tumors and pancreatic diseases (mainly pancreatic cancer, intraductal papillary mucinous neoplasms, acute and chronic pancreatitis). He has published more than 350 papers in international Journals and serves as a reviewer for leading journals in gastroenterology. He is Past President of the French Society of Gastroenterology and a member of numerous societies in the field of Gastroenterology, Pancreatology and Digestive Oncology. He served as Chairman of the European Neuroendocrine Tumor Society (ENETS) between 2010 and 2012.

Dr. Christos Toumpanakis, MD, PhD, FRCPath
Dr. Christos Toumpanakis, MD, PhD, FRCPath is a Consultant in Gastroenterology & Neuroendocrine Tumours in the Neuroendocrine Tumour Unit – ENETS Centre of Excellence of Royal Free Hospital, London, UK, since 2007. He is also an Honorary Senior Lecturer at University College of London, and has been awarded as “Top-Teacher of the Year” in 2007, 2009 and 2013. He graduated from Medical School-University of Athens in 1994, obtained his Specialty Title in Gastroenterology & Hepatology in 2004, and his PhD from University of Athens in 2007. He has been involved in the area of NETs since 2000. He has presented in several National & International Conferences and published many original papers and Reviews. He is a co-author of UK & Ireland NET Guidelines and a member of the Advisory Board of the “UK NET patients’ foundation”. He is leading a NETs Clinical Research Group and his main research interests include novel biomarkers and molecular imaging in NETs, mesenteric fibrosis and carcinoid heart disease.

Professor Juan W Valle, MB ChB MSc FRCP
Juan Valle is a Professor of Medical Oncology in the University of Manchester (Institute of Cancer Studies); part of the Manchester Academic Health Sciences Centre (MAHSC). He is based at The Christie NHS Foundation Trust within the Gastrointestinal Disease Group and treats cancers of the pancreas, liver and biliary tract, and neuroendocrine tumours. He is Head of Service for The Christie Neuroendocrine ENETS Centre of Excellence. Professor Valle is a member of the UK National Cancer Research Network (NCRN) Upper Gastrointestinal Clinical Studies Group and member of the hepatobiliary, and pancreatic subgroups; in addition he is Chair of the Neuroendocrine Subgroup. He has been awarded a number of grants for research leading to numerous publications and presentations and national and international meetings and is a peer-reviewer for a number of international medical journals. He is a member of ASCO (American Society of Clinical Oncology), ESMO (European Society of Medical Oncology), UKI NETS (UK and Ireland Neuroendocrine Tumour Society) and ENETS (European Neuroendocrine Tumour Society).

Tara Whyand, M.Sc, B.Sc
Tara Whyand, M.Sc, B.Sc, is the Oncology Dietitian specialising in Neuroendocrine Tumors at The Royal Free Hospital in London. She has recently co-authored several papers on diet, supplements and different cancers and for probiotics in gastrointestinal disorders. Last year Tara developed the most comprehensive Food and NETs booklet available. Tara is currently undertaking research using the Low FODMAP diet for controlling IBS symptoms in pancreatic and small bowel NETs. She regularly presents around the UK for the NET Patient Foundation and PLANET’s. Tara also undertakes freelance work, writing for Complete Nutrition magazine and advises a dietary supplement company. She has a keen interest in the area of nutraceuticals and probiotics regarding cancer growth. Previously Tara worked within the National Health Service, for the Cancer Council NSW and in the hospital catering industry.
Programme Postgraduate Course

Wednesday, 11 March 2015

The postgraduate programme is designed for clinicians and researchers new to NET diagnosis and therapy. Limited seats, prior online registration required! Fee: € 180 on site

09:15 - 17:10 5th ENETS Postgraduate Course 2015: Room 112

Chairs: M. Caplin, London, GBR
        R. Garcia-Carbonero, Madrid, ESP

08:15 - 09:15 REGISTRATION & COFFEE
Exhibition area

09:15 - 09:20 Introduction
M. Caplin, London, GBR

09:20 - 09:40 Epidemiology – Are numbers really rising?
D. O’Toole, Dublin, IRL

09:40 - 10:00 How useful is Ki67 – Should the G1-G3 values be changed?
A. Perren, Bern, SUI

10:00 - 10:10 Round-Table Discussion

10:10 - 10:30 The Flushing Patient but no NET found – What is the best approach?
A. Grossman, Oxford, GBR

10:30 - 11:00 Somatostatin Analogues – Where are we now?
M.E. Pavel, Berlin, GER

11:00 - 11:30 COFFEE BREAK
Exhibition area

11:30 - 11:50 Is there still a role for Transarterial Embolisation in NET Liver Mets?
P. Ruszniewski, Paris, FRA

11:50 - 12:10 Surgery for Small Intestinal NET – Should we also perform Cholecystectomy?
R. Kianmanesh, Reims, FRA

12:10 - 12:30 Midgut NET Case Presentation
C. Toumpanakis, London, GBR

12:30 - 12:45 Round-Table Discussion

12:45 - 13:45 LUNCH
Exhibition area

13:45 - 14:10 Carcinoid Heart Disease – A Less Invasive Management
K. Stangl, Berlin, GER

14:10 - 14:30 Molecular Targeted Therapies for Pancreatic NET – Does order matter?
J. Valle, Manchester, GBR

14:30 - 14:55 P-NET Case Presentation
M. Falconi, Milan, ITA

14:55 - 15:15 Nutritional Issues in NET and How to deal with them
T. Whyand, London, GBR

15:20 - 15:45 Endoscopic versus Surgical Therapy for Rectal NET – How to choose?
L. de Mestier, Reims, FRA

15:45 - 16:10 COFFEE BREAK
Exhibition area

16:10 - 16:35 Management of Paraganglioma and Phaeochromocytoma
D. Ferone, Genoa, ITA

16:35 - 17:00 Merkel Cell Tumours – Overview and Management Options
J. Becker, Essen, GBR

17:00 - 17:10 Summary and Closing Comments

17:15 - 18:15 WELCOME RECEPTION
Foyer in front of Room 112
### Meet the Professor Sessions

**Limited entrance! Prior online registration required per participant.**

All sessions held on the first Floor / Level P1. Breakfast will be served.

You can only attend one Meet the Professor session per day.

**07:30 - 08:25**

<table>
<thead>
<tr>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEN 1</td>
<td>Room 123</td>
</tr>
<tr>
<td>Liver Surgery</td>
<td>Room 124</td>
</tr>
<tr>
<td>Tricky NET Diagnosis in Pathology</td>
<td>Room 125</td>
</tr>
<tr>
<td>Optimal Imaging in NET Patients</td>
<td>Room 127</td>
</tr>
<tr>
<td>Difficulties in Diagnosing and Managing Zollinger Ellison Syndrom</td>
<td>Room 128</td>
</tr>
</tbody>
</table>

**Scientific Abstracts**

<table>
<thead>
<tr>
<th>Abstract</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Randomized Open-label Phase II Study of Everolimus Alone or in Combination with Pasireotide LAR in Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): COOPERATE-2 Trial</td>
<td>Room 123</td>
</tr>
<tr>
<td>CBEZ235Z2401: Randomized Phase II Study of BEZ235 or Everolimus (EVE) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET)</td>
<td>Room 127</td>
</tr>
</tbody>
</table>

### Session 1: Cancer Progression and Resistance

**Chairs:** G. Rindi, Rome, ITA  
E. Van Cutsem, Leuven, BEL

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:40 - 09:00</td>
<td>Cancer Evolution through space and time</td>
<td>C. Swanton, London, GBR</td>
<td>Room 113-116 (Plenary)</td>
</tr>
<tr>
<td>09:00 - 09:20</td>
<td>NET Epigenetics</td>
<td>C. Thirlwell, London, GBR</td>
<td>Room 113-116 (Plenary)</td>
</tr>
<tr>
<td>09:20 - 09:40</td>
<td>Drugable Targets – Commercial Assays</td>
<td>A. Meirovitz, Mevasseret Zion, ISR</td>
<td>Room 113-116 (Plenary)</td>
</tr>
<tr>
<td>09:40 - 10:00</td>
<td>Tumour Profiling for the Clinic – Are we ready?</td>
<td>M. Kulke, Boston, MA, USA</td>
<td>Room 113-116 (Plenary)</td>
</tr>
<tr>
<td>10:00 - 10:20</td>
<td>Discussion</td>
<td></td>
<td>Room 113-116 (Plenary)</td>
</tr>
</tbody>
</table>

### Session 2a: Clinical Abstracts

**Chairs:** N.S. Reed, Glasgow, GBR  
P. Ruszniewski, Paris, France

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 - 11:45</td>
<td>A Randomized Open-label Phase II Study of Everolimus Alone or in Combination with Pasireotide LAR in Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): COOPERATE-2 Trial</td>
<td>M. Kulke, Boston, MA, USA</td>
<td>Room 111</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>CBEZ235Z2401: Randomized Phase II Study of BEZ235 or Everolimus (EVE) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET)</td>
<td>S. Libutti, New York City, NY, USA</td>
<td>Room 111</td>
</tr>
</tbody>
</table>

### Session 2b: Basic Science Abstracts

**Chairs:** A. Couvelard, Paris, FRA  
B. Eriksson, Uppsala, SWE

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 - 11:45</td>
<td>mTOR Pathway Inhibition Sensitizes Insulinoma Cells to Streptozotocin Induced Apoptosis</td>
<td>C. Vercherat, Lyon, FRA</td>
<td>Room 111</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>Co-Expression of Somatostatin and CXCR4 Receptors as Targets for Diagnostics and Treatment in Intestinal Neuroendocrine Neoplasms</td>
<td>D. Kaemmerer, Bad Berka, GER</td>
<td>Room 111</td>
</tr>
</tbody>
</table>
### Session 2a: Rooms 113-116 (Plenary)

**12:00 - 12:15**
Localisation of Insulinoma and Beta-Cells: Comparison of Glucagon-Like Peptide-1 Receptor (GLP1-R) SPECT/CT, PET/CT and MRI. Preliminary Results of a Prospective Clinical Study  
*C. Rottenburger, Basel, SUI*

**12:15 - 12:30**
Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,258 Cases from 1993 through 2010  
*R.B. Cetinkaya, Oslo, NOR*

**12:30 - 12:45**
Contrast Harmonic Endoscopic Ultrasonography (CH-EUS) is Able to Predict Aggressiveness in Pancreatic Neuroendocrine Tumors  
*M. Palazzo, Clichy, FRA*

---

### Session 2b: Room 111

**12:00 - 12:15**
Tumor Infiltrating Lymphocytes and PD-L1 Expression Differ in Low and High Grade Neuroendocrine Tumors  
*P. Grabowski, Berlin, GER*

**12:15 - 12:30**
Receptor Tyrosine-Kinases Inhibition: New Insights on Therapeutic Implications of EGFR and IGF1R in Human Bronchopulmonary NET  
*T. Gagliano, Ferrara, ITA*

**12:30 - 12:45**
Filamin-A is Required for Somatostatin Receptor 2 (SST2) Stabilization, Signaling and Angiogenesis Regulation in Gastroenteropancreatic Neuroendocrine Tumors  
*E. Vitali, Rozzano, ITA*

---

### 11:35 - 12:35 Nurses Symposium, Session 2c:

Registration for the nurses symposium is free of charge.  
**Symposium** (industry-sponsored)  
**Chairs:**  
W. Geilvoet, Hekelingen, NED  
L.M. Plum, Copenhagen, DEN

**11:35 - 11:40**
Welcome and Introduction  
*P. Davies, London, GBR*

**11:40 - 11:50**
Summary of Quality of Life Survey Data, Local and International  
*M. Sissons, Hockley Heath, GBR*

**11:50 - 12:00**
Comparison of 24 Hour and Overnight Samples of Urinary 5-Hydroxyindoleacetic Acid in Patients with Intestinal Neuroendocrine Tumors  
*M. Gedde-Dahl, Oslo, NOR*

**12:00 - 12:10**
To explore what the True Lived Experience is of receiving these Molecular Targeted Agents  
*E. Quaglia, London, GBR*

**12:10 - 12:20**
NET-Nurse Quiz - A Digital Learning Tool  
*K.S. Mordal, Oslo, NOR*

**12:20 - 12:30**
Pancreatic Malignancy and Nutrition: A Study of Clinical Practice  
*L. McCallum, Prestwich, Manchester, GBR*

**12:30 - 12:35**
Q&A and Close  
W. Geilvoet, Hekelingen, NED  
L.M. Plum, Copenhagen, DEN

---

### 12:45 - 14:15 L U N C H + Satellite Symposium 1 (industry-sponsored) Room 112

For Symposium participants lunch boxes will be available in the meeting room.

### 14:15 - 15:15 Session 3a: MEN-1  
**Room 111**

**Chairs:**  
M.L. Brandi, Florence, ITA  
M. Falconi, Milan, ITA

**14:15 - 14:35**
Molecular Pathways  
*R. Thakker, Oxford, GBR*

**14:35 - 14:55**
Pancreatic and MEN-1 Case Presentation  
*K. Öberg, Uppsala, SWE*

**14:55 - 15:15**
Discussion on Surgery - Pro and Con  
*D. Bartsch, Marburg, GER  
F. Triponez, Genève, SUI*

---

### Session 3b: Rooms 113-116 (Plenary)

**14:15 - 14:30**
Gi Complications  
*U.F. Pape, Berlin, GER*

**14:30 - 14:45**
Functional Pancreatic NET: VIPoma, Insulinoma  
*I. Borbath, Bruxelles, BEL*

**14:45 - 15:00**
Management of Ectopic Hormones ACTH and GHRH  
*W. De Herder, Rotterdam, NED*

**15:00 - 15:15**
Short Case Resistance to SSTA in Carcinoid Syndrome  
*C. Tourpanakis, London, GBR*
### Session 4: Tumor Immunology and Local Environment

**Chairs:** A. Perren, Bern, SUI  
E. Raymond, Lausanne, SUI

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:40</td>
<td>Immunology Lessons for NET</td>
<td>Room 113-116 (Plenary)</td>
</tr>
<tr>
<td>16:10</td>
<td>Hypoxia HIF - Angiogenesis</td>
<td>Room 113-116 (Plenary)</td>
</tr>
<tr>
<td>16:35</td>
<td>Case Presentation of NET Immunotherapy</td>
<td>Room 113-116 (Plenary)</td>
</tr>
<tr>
<td>17:00</td>
<td>ENETS General Assembly</td>
<td>Room 111</td>
</tr>
</tbody>
</table>

### Satellite Symposium 2

(industry-sponsored)  
Room 112

### Friday, 13 March 2015

#### Meet the Professor Sessions

**Limited entrance! Prior online registration required per participant.**  
All sessions held on the first Floor / Level P1. Breakfast will be served.  
You can only attend one Meet the Professor session per day.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
</table>
| 08:30  | Meet the Professor Sessions | Room 123  
|       | MEN 1   | (industry-sponsored) |
| 08:30  | Liver Surgery | Room 124 |
|       | R. Kianmanesh, Reims, FRA |
|       | Tricky NET Diagnosis in Pathology | Room 125 |
|       | J.Y. Scoazec, Paris, FRA |
|       | Optimal Imaging in NET Patients | Room 127 |
|       | A. Sundin, Uppsala, SWE |
|       | Difficulties in Diagnosing and Managing Zollinger Ellison Syndrom | Room 128 |
|       | D. Metz, Philadelphia, PA, USA |

#### Session 5a: Familial NETs from Bench to Bedside

**Chairs:** W. De Herder, Rotterdam, NED  
G. Kaltsas, Athens, GRE

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Meet the Professor Sessions</td>
<td>Room 111</td>
</tr>
</tbody>
</table>
| 08:30  | Men-2 Genetics and Clinical Relevance | Room 123  
|       | O. Gimm, Linköping, SWE |
| 08:50  | Familial Paragangliomas: Genetics and Clinical Relevance | Room 124 |
|       | A.P. Gimenez-Roqueplo, Paris, FRA |
| 09:10  | Familial NET Case Discussion | Room 125 |
|       | A. Grossman, Oxford, GBR |
| 09:30  | Presidential Abstract: M-TORC1 Complex is Significantly Over-Activated in SDHx-Mutated Paragangliomas | Room 127 |
|       | M. Volante, Turin, ITA |

### Session 5b: Mixed Adeno-NET

**Chairs:** J. Capdevila, Barcelona, ESP  
F. Costa, Sao Paulo, BRA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Mixed Adeno-NET</td>
<td>Rooms 113-116 (Plenary)</td>
</tr>
<tr>
<td>08:30</td>
<td>MANEC Pathology</td>
<td>Room 113-116 (Plenary)</td>
</tr>
<tr>
<td>08:45</td>
<td>MANEC Management</td>
<td>Room 113-116 (Plenary)</td>
</tr>
<tr>
<td>09:00</td>
<td>Neuroendocrine Differentiation and Management in Urological/Prostate NET</td>
<td>Room 113-116 (Plenary)</td>
</tr>
<tr>
<td></td>
<td>A. Berruti, Brescia, ITA</td>
<td></td>
</tr>
<tr>
<td>09:20</td>
<td>Panel Discussion</td>
<td>Room 113-116 (Plenary)</td>
</tr>
<tr>
<td>09:30</td>
<td>Presidential Abstract: Histological Classification of Pancreatic Neuroendocrine Tumours - Optimising the Ki67 System</td>
<td>Room 113-116 (Plenary)</td>
</tr>
<tr>
<td></td>
<td>L. Mills, Coventry, GBR</td>
<td></td>
</tr>
</tbody>
</table>

#### Session 6: Clinical Use of GPCR Advances in Nuclear Medicine

**Chairs:** J.B. Cwikla, Warsaw, POL  
D. Kwekkeboom, Rotterdam, NED

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:45</td>
<td>Clinical Use of GPCR Advances in Nuclear Medicine</td>
<td>Rooms 113-116 (Plenary)</td>
</tr>
<tr>
<td>09:45</td>
<td>Ga68 and Lu-177 DOTA TATE/NOC/TOC Imaging and Therapy - Any Difference</td>
<td>Room 113-116 (Plenary)</td>
</tr>
<tr>
<td></td>
<td>L. Bodei, Milan, ITA</td>
<td></td>
</tr>
</tbody>
</table>
### Scientific Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:05 - 10:25</td>
<td>New Isotope for Diagnosis of NET</td>
<td>A. Kjaer, Copenhagen, DEN</td>
</tr>
<tr>
<td>10:25 - 10:45</td>
<td>Case Presentation for New Imaging in Difficult to find NET GLP1</td>
<td>D. Wild, Basel, SUI</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>Presidential Abstract: Functional Imaging Tests versus Computed Tomography Scan: Detection of New Metastases and Clinical Usefulness in Digestive Neuroendocrine Neoplasms Follow-Up</td>
<td>E. Merola, Roma, ITA</td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td>Coffee Break and Poster Viewing (Ground Floor)</td>
<td></td>
</tr>
<tr>
<td>11:30 - 12:30</td>
<td>Session 7: Pulmonary NETs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: P. Ferolla, Perugia, ITA</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>P.L. Filosso, Torino, ITA</td>
</tr>
<tr>
<td>11:30 - 11:50</td>
<td>Epidemiology and Pathology - Do we need to change the Nomenclature?</td>
<td></td>
</tr>
<tr>
<td>11:50 - 12:10</td>
<td>Medical Management of Advanced Pulmonary NET</td>
<td></td>
</tr>
<tr>
<td>12:10 - 12:30</td>
<td>Case Presentation of Thoracic NET</td>
<td></td>
</tr>
<tr>
<td>12:30 - 13:00</td>
<td>Keynote Lecture: Medullary Thyroid Carcinoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>R. Elisei, Pisa</td>
<td></td>
</tr>
<tr>
<td>13:00 - 14:15</td>
<td>Lunch and Satellite Symposium 3 (industry-sponsored)</td>
<td></td>
</tr>
<tr>
<td>14:15 - 15:30</td>
<td>Session 8a: Biomarkers Outside Chromogranin and Beyond</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: D. Gross, Mevasseret Zion, ISR</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>W. Weber, New York City, NY, USA</td>
</tr>
<tr>
<td>14:15 - 14:30</td>
<td>mi RNA</td>
<td></td>
</tr>
<tr>
<td>14:30 - 14:45</td>
<td>mRNA and Serum Markers</td>
<td></td>
</tr>
<tr>
<td>14:45 - 15:00</td>
<td>Circulating CTC and DNA</td>
<td></td>
</tr>
<tr>
<td>15:00 - 15:15</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>15:15 - 15:30</td>
<td>Presidential Abstract: Molecular Profiling of Small Intestinal Neuroendocrine Tumours (SINETs)</td>
<td></td>
</tr>
<tr>
<td>15:30 - 15:50</td>
<td>Coffee Break and Poster Viewing (Ground Floor)</td>
<td></td>
</tr>
<tr>
<td>15:50 - 16:35</td>
<td>Session 9: What’s new in the field?</td>
<td></td>
</tr>
<tr>
<td>16:05 - 16:20</td>
<td>Basic Science</td>
<td></td>
</tr>
<tr>
<td>16:20 - 16:35</td>
<td>Overview of Clinical Trials</td>
<td></td>
</tr>
<tr>
<td>16:35 - 17:05</td>
<td>Grants and Awards Ceremony</td>
<td></td>
</tr>
<tr>
<td>17:05 - 17:15</td>
<td>Closing Comments Annual Meeting</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**
- Rooms 113-116 (Plenary)
- Exhibition area
- For Symposium participants lunch boxes will be available in the meeting room.
The titles of all approved abstracts include first authors and are listed here:

**A. BASIC SCIENCE - MTOR AND OTHER PATHWAYS, SIGNALLING, RECEPTORS**

(A1) Avniel-Polak S et al. Abrogation of Autophagy by Chloroquine in Neuroendocrine Tumor Cells Treated with mTOR Inhibitors Induces Apoptosis, While Reduction of Cell Proliferation Is Due to a Chloroquine, Autophagy Unrelated, Lysosomal Effect

(A2) Benfini K et al. p27kip1 Is Involved in the Resistance of Human Bronchial Carcinoids to m-TOR Inhibitors

(A3) Falletta S et al. mTOR Down-Stream Signaling Pattern May Predict pNET Response to Everolimus

(A4) Falletta S et al. Role of TGF beta-1 in Regulating Pancreatic Neuroendocrine Tumor Cell Viability

(A5) Freitag H et al. Dual Inhibition of PI3K and mTORC1/C2 by PKI-587 (PF-05212384) as a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease and Its Effect on AKT-Signaling

(A6) Gagliano T et al. Receptor Tyrosine-Kinases Inhibition: New Insights on Therapeutic Implications of EGFR and IGF1R in Human Bronchopulmonary NET

(A7) Hoffmeister M et al. Role of Amplifications in the PIK3/Akt/mTOR-Pathway in Neuroendocrine Tumors of the Small Intestine

(A8) Kaemmerer D et al. Co-Expression of Somatostatin and CXCR4 Receptors as Targets for Diagnostics and Treatment in Intestinal Neuroendocrine Neoplasms

(A9) Neumayer B et al. Significance of ATRX/DAXX Expression and Alternative Lengthening of Telomeres in Insulinomas and Neuroendocrine Tumors of Small Intestine

(A10) Oudijk L et al. M-TORC1 Complex Is Significantly Over-Activated in SDHx-Mutated Paragangliomas

(A11) Peters M et al. Platelet Serotonin But Not Dopamine Concentrations Are Lower in Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Patients Compared to Healthy Individuals

(A12) Sciammarella C et al. Expression and Role of the CXCR4/CXCL12/CXCR7 Axis and Crosstalk with the mTOR Pathway in Neuroendocrine Tumors (NETs)

(A13) Vercherat C et al. mTOR Pathway Inhibition Sensitizes Insulinoma Cells to Streptozotocin Induced Apoptosis

(A14) Vitali E et al. Filamin-A Is Required for Somatostatin Receptor 2 (SST2) Stabilization, Signaling and Angiogenesis Regulation in Gastroenteropancreatic Neuroendocrine Tumors

(A15) Wiedmer T et al. Autophagy as a Possible Mechanism of Resistance in pNET Treatment

**B. BASIC SCIENCE - GENETICS, EPIGENETICS, MIRNAS**

(B1) Campa D et al. Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A/P16) Polymorphisms and Risk of Pancreatic Neuroendocrine Tumors

(B2) Karpathakis A et al. Molecular Profiling of Small Intestinal Neuroendocrine Tumours (SINETs)

(B3) Kim S et al. Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in Precision-Medicine Era

(B4) Pfgragner R et al. A Novel Human Cell Line from Familial Medullary Thyroid Carcinoma

(B5) Qiao XW et al. Comparative Proteomic Analysis of Human Insulinoma and Its Clinical Implications in Pancreatic Neuroendocrine Tumors

(B6) Shi H et al. Functional Role of miR-196a in Neuroendocrine Tumor Cells

(B7) Song YL et al. Exclusive Hotspot Mutation of YY1 Gene in Insulinomas and Extensive Mutation of DAXX in PNETs

(B8) Veenstra MJ et al. Epigenetic Manipulation of the Somatostatin Receptor Type 2 in Neuroendocrine Tumor Cells

(B9) Xiaokun G et al. Androgens Regulate SMAD Ubiquitination Regulatory Factor-1 Expression and Prostate Cancer Cell Invasion

**C. BASIC SCIENCE - IN VITRO MODELS, TUMOR GROWTH, CTCS**

(C1) Bellio M et al. Investigation of the Effects of Sunitinib on Pheochromocytoma and Paraganglioma Primary Cultures

(C2) Gaudenzi G et al. Zebrafish as a New In Vivo Model to Study Angiogenesis in Neuroendocrine Tumors (NET)

(C3) Gentilin E et al. Mitotane, Adrenolitic Drug, Inhibits Cell Survival and Function of Several Pituitary Cytotypes

(C4) Kleinegger F et al. Cancer Stem Cells in Small Intestine Neuroendocrine Cell Line P-STS: Isolation and Molecular Characterisation

(C5) Krug S et al. The Impact of Pharmacological-Mediated Depletion of Macrophages in Pancreatic Neuroendocrine Neoplasms

(C6) Schrader J et al. Establishment of a New Human Pancreatic Neuroendocrine Tumour Cell Line

**D. EPIDEMIOLOGY/NATURAL HISTORY/PROGNOSIS - REGISTRIES, NATIONWIDE AND REGIONAL SURVEYS**

(D1) Borbath I et al. The Belgian DNET Registry: A Prospective, National, Web-Based Registry of Digestive Neuro-Endocrine Tumours (NET). Status After 2 Years of Inclusion

(D2) Bouvier C et al. United Kingdom NET Patient Survey Quality of Life Results
Abstract Titles


(D4) Komarova L et al. NETs in Hospital Registry of Russian Cancer Center

(D5) Kornerup LS et al. Survival and Predictors of Death for Patients with Bronchopulmonary Carcinoids in a Danish Tertiary NET Center

(D6) Sandvik O et al. Epidemiology and Classification of Gastroenteropancreatic Neuroendocrine Neoplasms Using the WHO 2010 Criteria: A Cohort Study in a Defined Norwegian Population

(D7) Van der Zwan JM et al. European Information Network on Rare Cancers (RARECAREnet)

E. EPIDEMIOLOGY/NATURAL HISTORY/PROGNOSIS - PROGNOSIS

(E1) Carmona-Bayonas A et al. Prognosis of Stage IV Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) According to the WHO Classification and the Primary Tumor Location

(E2) Davi’ MV et al. Follow Up of ≤ 2 cm Non Functioning Pancreatic NETs in Patients with MEN1 Treated with Conservative Approach

(E3) Felder S et al. Gastric Neuroendocrine Neoplasias-Outcome Predictors-ENETS Staging and Grading System and Treatment

(E4) Jilesen A et al. Recurrent Disease After Curative Pancreatic Resection for Patients with Non-Functional Neuroendocrine Tumor; Identify the High Risk Patient

(E5) Kamp K et al. GastroEnteroPancreatic and Thoracic Neuroendocrine Tumors and the Ectopic Adrenocorticotropin Syndrome

(E6) Lamarca A et al. Appendiceal Goblet Cell Carcinoids: Prognostic Factors and Selection of the Most Appropriate Adjuvant Management in a Retrospective Series

(E7) Massironi S et al. ”Wait and Watch” Approach for Small Pancreatic Neuroendocrine Tumors (pNETs): Prognosis and Survival in 51 Consecutive Patients

(E8) Milanetto AC et al. 38 Years of Experience in a Single Centre on Neuroendocrine Pancreatico-Duodenal Tumors in Multiple Endocrine Neoplasia Type 1 Syndrome

(E9) Ribeiro C et al. Describing NENs: Just Clinical/Biologic Features or Actual Prognostic Factors?

(E10) Richards-Taylor S et al. Ki67 as a Prognostic Marker in Neuroendocrine Tumours: A Systematic Review of the Literature and Quantitative Synthesis of 5 year Survival Data

(E11) Schmidt L et al. Comparative Marker Assessment in Small Cell Lung Cancer with Good and Poor Prognosis

(E12) Tamburrino D et al. Management and Clinical Outcome of Patients with MEN 1 Disease Presenting Non Functioning Pancreatic Neuroendocrine Neoplasms (NF-pNEN) ≤ 2 cm

F. EPIDEMIOLOGY/NATURAL HISTORY/PROGNOSIS - DESCRIPTIVE EPIDEMIOLOGY

(F1) Alexandraki K et al. Ectopic Cushing’s Syndrome (ECS) in Patients with Neuroendocrine Neoplasms

(F2) Christensen CU et al. Pancreatic Neuroendocrine Tumors in Denmark and Introduction of Cancer Package Pathways

(F3) Grimaldi F et al. Trends in Neuroendocrine Tumor in Friuli Venezia Giulia in the Last 20 Years

(F4) Price T et al. The Clinical Oncology Society of Australia (COSA) SIGNETURe Neuroendocrine Tumor (NET) Registry of Australia: First Report of Patient Characteristics and Patterns of Care

(F5) Rinzivillo M et al. Risk and Protective Factors for Midgut Carcinoid Tumours: A Case-Control Study of Prospectively Evaluated Patients

(F6) Santos D et al. Cardiac Evaluation as Part of the Initial Extension Studies in Neuroendocrine Tumors. Experience in a Multidisciplinary Team. ARGENTUM GROUP

(F7) Santos AP et al. Preliminary Results on the Diagnosis of NETs in Portugal – The Cross Sectional TNE-ETC Survey

(F8) Wang J et al. Epidemiologic Analysis of Neuroendocrine Tumors in Cancer Center: Tianjin, China

(F9) Yalchin M et al. Epidemiological Characteristics from a Single Centre Database Cohort of 1301 Neuroendocrine Tumor Patients: Is There an Association Between Age and Grade of NET?

G. PATHOLOGY, GRADING, STAGING

(G1) Blank A et al. Interlaboratory Variability of MIB1 Staining in Well Differentiated Pancreatic Neuroendocrine Tumors

(G2) Bucu M et al. Correlation Between the 18F-FDG Uptake and Pathological Data in Well-Differentiated Digestive and Pulmonary Neuroendocrine Tumors (NET)

(G3) Cives M et al. Significance of Ectopic Lymph Node-Like Structures in Neuroendocrine Tumors of the Small Bowel

(G4) Delektorskaya V et al. Expression and Clinical Significance of Merkel Cell Polyomavirus Large T Antigen in Merkel Cell Carcinoma

(G5) Dema A et al. Neuroendocrine Carcinomas of the Prostate


(G7) Milione M et al. Clínico-Pathologic: Survival Analysis of 211 GastroEnteroPancreatic G3 Neuroendocrine Carcinomas (GEP-NECs)

(G8) Mills L et al. Histological Classification of Pancreatic Neuroendocrine Tumours: Optimising the Ki67 System
H. BIOMARKERS

(H1) Alaimo D et al. Neuroendocrine Gene Transcript Analysis of Blood Identifies Stable or Progressive NET Disease Treated with Somatostatin Analogs

(H2) Basuroy R et al. An Isolated Abnormal Chromogranin B Is Associated with Pancreato-Duodenal NETs and the Presence of Liver Metastases

(H3) Belli S et al. Correlation of Serum Plasma Chromogranin A with Survival and Disease Features in Patients with Gastroenteropancreatic Neuroendocrine Tumors. First Results in a Large Database in Argentina. ARGENTUM GROUP

(H4) Berardi R et al. Impact of VEGF and VEGFR Polymorphisms on Neuroendocrine Tumors of the Gastro-Entero-Pancreatic System (GEP-NET) Outcome

(H5) Bodei L et al. Blood Gene Transcript Analysis Predicts 68Ga-SSA-PET/CT Imaging in Neuroendocrine Tumors and Defines Disease Status

(H6) Bodei L et al. Measurement of Blood Gene Transcripts Defines PRRT Therapeutic Efficacy

(H7) Boutzios G et al. The Association Between Gastrin and Glucose Serum Concentration

(H8) Cameron S et al. Changes in Neuroendocrine Tumor Microenvironment with WHO Tumor Grading

(H9) Carsote M et al. The Neuron-Specific Enolase Assessment in Patients with Neuroendocrine Tumors with or without Carcinoid Syndrome

(H10) Glinicki P et al. Chromogranin A (CgA) in Pheochromocytoma and in Multiple Endocrine Neoplasia Type 1

(H11) Grabowski P et al. Tumor Infiltrating Lymphocytes and PD-L1 Expression Differ in Low and High Grade Neuroendocrine Tumors

(H12) Kidd M et al. Circulating Gene Transcript Analysis of Pancreatic NETs


(H14) Mills L et al. CA 19-9: A Novel Role in the Prognosis of Pancreatic Neuroendocrine Tumors 94

(H15) Nozière C et al. High Thyrocalcitonin Serum Level in Neuroendocrine Tumors: Characteristics, Prognosis and Interest in Follow-Up?

(H16) Strosberg J et al. Identification of Response Predictors to Temozolomide-Based Chemotherapy

I. IMAGING (RADIOLOGY, NUCLEAR MEDICINE, ENDOSCOPY)

(I1) Bailey D et al. Characterisation, Measurement and Biodistribution of an Improved Formulation of [Lu-177]-Octreotate

(I2) Baur A et al. Signs of Carcinoid Heart Disease on Staging CT: Which Predictors are Helpful?

(I3) Dimitroulopoulos D et al. A Comparative Study Among Several Imaging Methods for the Detection of Primary and Metastatic Sites of GEP-NETs

(I4) Jiang LM et al. CT Imaging Findings of Gastric Neuroendocrine Neoplasm According to 2010 WHO Classification

(I5) Jilesen A et al. The Additional Value of Somatostatin Receptor Scintigraphy During Preoperative Staging in Patients with Non-Functioning Pancreatic Neuroendocrine Tumors

(I6) Li Y et al. CT Evaluation of Gastric Neuroendocrine Neoplasm Based on WHO 2010 Classification

(I7) Maiti D et al. Role of Enteroclysis MDTC in the Diagnosis and Follow-Up of ileal Neuroendocrine Tumors

(I8) Merola E et al. Functional Imaging Tests versus Computed Tomography Scan: Detection of New Metastases and Clinical Usefulness in Pancreatic Neuroendocrine Neoplasms Follow-Up

(I9) Ortolani S et al. Role of Combined 68Ga-DOTATOC and 18F-FDG PET-CT in the Diagnostic Workup of Well Differentiated Pancreas Neuroendocrine Tumors (PanNETs): A Surgical Series

(I10) Ortolani S et al. Perfusion Changes in Liver Metastases (LM) from Pancreatic Neuroendocrine Tumors (PanNETs) during Everolimus (E) Treatment: Update of Perfusion CT (P-CT) Study

(I11) Palazzo M et al. Contrast Harmonic Endoscopic Ultrasonography (CH-EUS) is Able to Predict Aggressivity in Pancreatic Neuroendocrine Tumors

(I12) Prasad V et al. Ga-68 Somatostatin Receptor PET/CT in the Detection of Insulinoma.

(I13) Rinzivillo M et al. Prognostic Role of FDG-PET in Advanced Digestive Neuroendocrine Neoplasms

(I14) Rodriguez-Laval V et al. Small Bowel Neuroendocrine Tumors (NET): Relationship Between Radiologic Features, Functionality and Ki-67 Classification

(I15) Rottenburger C et al. Localisation of Insulinoma and Beta-Cells: Comparison of Glucagon-Like Peptide-1 Receptor (GLP1-R) SPEC/TCT, PET/CT and MRI. Preliminary Results of a Prospective Clinical Study

(I16) Sergieva S et al. New Hybrid SPECT-CT Modality for Imaging Purposes in Patients with Medullary Thyroid Cancer (MTC)


(I18) Van Binnebeek S et al. Pre-PRRT Uptake on 68Ga-DOTATOC Predicts Good Prognosis in Neuroendocrine Tumors Patients

(I19) Yu J et al. An Intrapatient Comparison of 99mTc-HYNIC-TOC with 68Ga-DOTA-TATE for Imaging Abilities of Gastroenteropancreatic Neuroendocrine Neoplasms
Abstract Titles

J. MEDICAL TREATMENT - CHEMOTHERAPY

(J1) Apostolidis L et al. Efficacy of Topotecan in Pretreated Metastatic Neuroendocrine Carcinoma

(J2) Bongiovanni A et al. First-Line Chemotherapy in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC): A Retrospective Analysis

(J3) Dussol AS et al. Gemox or Alkylating Agents in Neuroendocrine Tumors? The Help of O6-Methylguanine-DNA Methyltransferase (MGMT) Status?

(J4) Gagliano T et al. TIM16 Inhibition Decreases Calcitonin Secretion and Enhances Sensitivity to Paclitaxel in a Human Medullary Thyroid Carcinoma Cells

(J5) Jia R et al. Clinical Characteristics and Treatment Outcome of Six Advanced G3 Well-Differentiated Neuroendocrine Tumors

(J6) Jimenez-Fonseca P et al. Streptozotocin Based Chemotherapy in Advanced G2 Pancreatic Neuroendocrine Tumors (PNET): Efficacy According to Ki67 Index

(J7) Kiesewetter B et al. Lack of Efficacy of Anthracycline-Containing Second Line Chemotherapy in Patients with GI-NEC After Cisplatin-Based Treatment

(J8) Liu L et al. Unresectable Gastrointestinal Neuroendocrine Liver Metastases Treated by Liver-Directed Therapies

(J9) Maasberg S et al. Temozolomid-Based Therapy in GEP-and Bronchopulmonary NEN from a Multicentric Study from Germany

(J10) Marconcini R et al. Retrospective Comparison of Chemotherapy Treatment with Capecitabine Alone or Fluropirimidine Plus Oxaliplatin in Advanced and Pretreated NET

(J11) Spada F et al. Chemotherapy with Capecitabine plus Temozolomide (CAP-TEM) in Patients with Advanced Neuroendocrine Neoplasms (NENs): An Italian Multicenter Retrospective Analysis

(J12) Walter T et al. Evaluation of the Combination Oxaliplatin and 5-Fluorouracil or Gemcitabine in Patients with Metastatic Lung Carcinoid Tumors

K. MEDICAL TREATMENT - SMS ANALOGUES, INTERFERON

(K1) Buil-Bruna N et al. Population Pharmacokinetic (PK) Analysis of Lanreotide Autogel (LAN) in the Treatment of Patients (pts) with NETs: Pooled Analysis of Four Clinical Trials

(K2) Caplin ME et al. Lanreotide Autogel (LAN) 120 mg in Patients with Progressive Enteropancreatic (EP-)NETs: Data from the CLARINET Open-Label Extension (OLE) Study

(K3) Caplin ME et al. Antitumor Treatment with Lanreotide Autogel 120 mg (LAN) for Enteropancreatic (EP-)NET: Update from the CLARINET Open-Label Extension (OLE) Study

(K4) Caplin ME et al. Health-Related Quality of Life (HRQoL) with Lanreotide Autogel (LAN) 120 mg in Patients with Enteropancreatic (EP-)NETs: Post Hoc Analyses from the CLARINET Study

(K5) Caplin ME et al. Chromogranin A (CgA) and PFS Outcomes in Lanreotide Autogel (LAN) in Patients with Metastatic Enteropancreatic (EP-)NETs: Data from the CLARINET Study

(K6) Gorbunova V et al. IFN versus IFN Plus Octreotide LAR in Treatment of NETs

(K7) Karra E et al. Somatostatin Analogues in Bronchial Neuroendocrine Tumors: Symptom Control and Anti-Proliferative Role

(K8) Modica R et al. High-Dose Treatment with Somatostatin Analogs in Neuroendocrine Tumors

(K9) Ramundo V et al. Efficacy of Lanreotide versus Follow-up in Early-stage Duodeno-Pancreatic Neuroendocrine Tumors (NETs) Related to Multiple Endocrine Neoplasia Type 1 (MEN1): Preliminary Data

(K10) Ruszniewski P et al. Treatment Satisfaction, Symptom Control and Quality of Life (QoL) with Lanreotide Autogel (LAN) in NET Patients with Carcinoid Syndrome (CS): Results from the SYMNET Study

(K11) Toumpanakis C et al. Predictive Factors for Antiproliferative Activity of Octreotide LAR in Advanced Neuroendocrine Tumors

(K12) Weickert MO et al. Somatostatin Responsive ACTH and Precursor Excess in a Midgut Mesentery NET

L. MEDICAL TREATMENT - TARGETED THERAPIES

(L1) Apostolidis L et al. Experience with Bevacizumab in Neuroendocrine Tumors

(L2) Bacher M et al. Results of Sunitinib Treatment of Advanced Neuroendocrine Neoplasms: “Real-life” Outcome Data from the German NET-Register

(L3) Benslama N et al. Clinico-Biological and Histological Predictive Factors and Markers of Response to Everolimus in Neuroendocrine Tumors

(L4) Birocco N et al. Pancreatic Location, High Proliferation and Low p-mTOR Expression Levels Are More Frequent in Neuroendocrine Tumor Patients Responsive to mTOR Inhibitors: Results from a Preliminary Study

(L5) Cives M et al. A Phase II Study of Axitinib in Advanced Carcinoid Tumors: Preliminary Results

(L6) Cros J et al. Gly388Arg FGFR4 Polymorphism is Not Predictive of Everolimus Efficacy in Gastrointestinal Well Differentiated Neuroendocrine Tumors (NET)
Abstract

(P1) Derks JL et al. A National Pathology Registration Analysis of Applied Terminology in Pulmonary Neuroendocrine Tumors/Carcinomas: Is the WHO 2004 Classification in Line with Clinical Practice?

(P2) Derks JL et al. Clinical Characteristics and Overall Survival of Large Cell Neuroendocrine Carcinoma (LCNEC) Compared to Other Subtypes of Lung Cancer: Results of a Population-based Registry

(P3) Geraldo Roig L et al. Atypical Bronchial Carcinoid: Different Therapeutical Approaches

(P4) Gianoncelli L et al. Everolimus in Patients (pts) with Advanced Lung Carcinoids: Evaluation of Median Progression Free Survival (PFS) and Median Time to First Dose Decrease or Discontinuation (DDD)


(P6) Walter T et al. Characterization and Prognosis of Patients with Metastatic Lung Carcinoid Receiving Hemodialysis

Q. CLINICAL CASES/REPORTS

(Q1) Brizzi MP et al. Use of Everolimus in a Patient with Metastatic Bronchial Carcinoid Receiving Hemodialysis

(Q2) Cabanne A et al. Mixed Adenoneuroendocrine Carcinomas (MANECs) of the Gastrointestinal Tract. ARGENTUM Group

(Q3) Cavalcoti F et al. Gastric Neuroendocrine Neoplasms and Long-Term Proton Pump Inhibitors: Need for a Revision of Classifications?

(Q4) Clift A et al. Second Primary Malignancies in Patients with Neuroendocrine Tumors

(Q5) Clift A et al. A Novel Approach for a Metastatic Gut-Derived Neuroendocrine Tumour: Simultaneous Intestinal and Vascularised Sentinel Forearm Flap Transplantation

(Q6) Defour L et al. Regression of Paraneoplastic Optic Neuropathy Associated with Glucagonoma After Surgical Resection

(Q7) Huang D et al. Clinicopathologic Characteristics of Gastric Amphicrine Carcinoma at a Single Institution

(Q8) Iacovazzo D et al. A Novel MEN1 Gene Variant in a Sporadic Case of Multiple Endocrine Neoplasia Type 1

(Q9) Kump P et al. Fifty-Three Year-Old-Male with a Symptomatic Ileocecal Carcinoid: An Individual Follow-Up of 14 Yrs with 5 Different Anti-Proliferative Therapies

(Q10) Lico V et al. Pancreatic Neuroendocrine Tumor and Ileal Carcinoid in Acromegaly. Pluriglandular Association in Non-MEN 1 Patient: A Case Report

(Q11) Linder Ekberg K et al. 68 Yr Female with a Growing Inoperable Myocardial Metastase

(Q12) Moletta L et al. Neuroendocrine Pancreatic Tumor Associated with a Cerebral Neurofibroma. A Case Report

(Q13) Mulcahy V et al. Case Report of Recurrent VIPoma

(Q14) Nakazuru S et al. Simultaneous Large Cell Neuroendocrine Carcinoma and Adenocarcinoma of the Stomach: A Case Report and Literature Review

(Q15) Piacentini S et al. Two Cases of Ectopic ACTH-Secreting Neoplasm of Occult Origin Becoming Overt After Bilateral Adrenalectomy

(Q16) Ploner F et al. Hypoglycaemia in a Patient with Glucagonoma-Coincidence of a Glucagonoma and Insulinoma in a Patient with Multiple Endocrine Neoplasia Type I

(Q17) Pschowski R et al. Staged Percutaneous Treatment of Severe Carcinoid Heart Disease by Transfemoral Pulmonary Valve Replacement and Novel Vena Cava Valve Implantation

(Q18) Rho YS et al. Targeted Therapies as First Line Option in Very Advanced Unresectable Pancreatic Neuroendocrine Tumors

(Q19) Ringholm L et al. Cowden Syndrome and Concomitant Pulmonary Neuroendocrine Tumor: A Presentation of Two Cases

(Q20) Robev B et al. Optimal Clinical Effect of Sandostatin LAR Treatment for Gastroenteropancreatic (GEP) Carcinoid
<table>
<thead>
<tr>
<th>Abstract</th>
<th>Titles</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Q21)</td>
<td>Sherriff D et al. Malignant Insulinoma in a Patient with Diabetes: Response to Treatment and a Return to Insulin Injections</td>
</tr>
<tr>
<td>(Q22)</td>
<td>Vaslamatzis M et al. Antiproliferative Effect of Lanreotide in Low Grade Neuroendocrine Neoplasms: Two Case Reports</td>
</tr>
<tr>
<td>(Q23)</td>
<td>Yalchin M et al. Salvage Treatment with Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Advanced VIPomas and Severe Verner-Morrison Syndrome</td>
</tr>
<tr>
<td>(Q24)</td>
<td>Yalchin M et al. Role of Cytoreductive Surgery (CRS) and Intraoperative Hyperthermic intraperitoneal Chemotherapy (HIPEC) for High Grade Neuroendocrine Tumour</td>
</tr>
<tr>
<td>(Q25)</td>
<td>Zhang C et al. Subtype Classification and Clinicopathological Characteristics of 78 Cases with Gastric Neuroendocrine Neoplasms</td>
</tr>
<tr>
<td>(Q26)</td>
<td>Zhao H et al. Clinicopathological Features and Prognostic Factors of Gastric Neuroendocrine Tumors: A Retrospective Analysis of 69 Cases</td>
</tr>
</tbody>
</table>

| R1       | Corcos O et al. Mesenteric Ischemia Due to Neuroendocrine Tumors of the Digestive Tract |
| R2       | Han X et al. Identification of Novel and Pathological Feature of Angiostatic Microvasculature in Liver Metastatic Pancreatic Neuroendocrine Tumors and Its Clinical Implication |
| R3       | Leyden J et al. The Neuroendocrine Tumor (NET) Patient (pt) Perspective: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals |
| R4       | Maurizi A et al. Health-Related Quality of Life in Patients after Diagnosis of Nonfunctioning Asymptomatic Pancreatic Neuroendocrine Neoplasms (PNEN) <= 2 cm |
| R5       | Nada H et al. Appendiceal Neuroendocrine Tumor: Correlation Between Histopathological Factors |
| R6       | Öberg K et al. Multidisciplinary Team (MDT) in Neuroendocrine Tumor (NET) Management: Results from the First Global NET Patient (pt) Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals |
| R7       | Passegger C et al. The Chicken Chorioallantoic Membrane Assay as a Preclinical Model for the Research of Rare Gastrointestinal Neuroendocrine Tumours |
| R8       | Pavel M et al. Time to Diagnosis of Neuroendocrine Tumors (NETs): Results from the First Global NET Patient (pt) Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals |
| R9       | Ruszniewski P et al. Neuroendocrine Tumor (NET) Patient (pt) Experience and Disease Burden: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals |
| R10      | Schwach G et al. Epirubicin Loaded Polyphosphazene; A New Agent Against Small Intestinal Neuroendocrine Tumors and Medullary Thyroid Carcinomas |
| R11      | Ueda K et al. Usefulness of a Combination of a 48-Hour Fasting and a Glucagon Tolerance Test |
Abstract Review Committee Lead
Nick Reed GBR

Basic Science Abstract Reviewers 2015
Detlef Bartsch GER
Anne Couvelard FRA
Diego Ferone ITA
David Gross ISR
Ashley Grossman GBR
Gregory Kaltsas GRE
Aurel Perren SUI
Guido Rindi ITA
Aldo Scarpa ITA
Wolfgang Weber GER

Clinical Abstract Reviewers 2015
Wouter De Herder NED
Barbro Eriksson SWE
Rocio Garcia Carbonero ESP
Ulrich Knigge DEN
Juan O’Connor ARG
Andreas Pascher GER
John Ramage GBR
Nick Reed GBR
Philipp Ruszniewski FRA
Halfdan Sorbye NOR
Anders Sundin SWE
### CoE Young Investigator Grant Review Committee

- Dermot O'Toole  IRL (Lead)
- Rocio Garcia-Carbonero  ESP
- Reza Kianmanesh  FRA
- Günther Klöppel  GER
- Mathew Kulke  USA
- Kjell Öberg  SWE

### Excellence in Translational Medicine in GEP-NET Disease Grant Review Committee

- Aurel Perren  SUI (Lead)
- Robert Jensen  USA
- Ramon Salazar  ESP
- Juan Valle  GBR

### Hakan Ahlman Award Review Committee

- Kjell Öberg  SWE (Lead)
- Gianfranco Delle Fave  ITA
- Ulrich Knigge  DEN
- Bruno Niederle  AUT
- Marianne Pavel  GER
- Aldo Scarpo  ITA

### CoE Young Training Grant Review Committee

- Massimo Falconi  ITA (Lead)
- Martyn Caplin  GBR
- Ashley Grossman  GBR
- Wouter de Herder  NED
- Guido Rindi  ITA

### Travel Grant Review Committee

- Marianne Pavel  GER (Lead)
- Massimo Falconi  ITA
- Ashley Grossman  GBR
- Philippe Ruszniewski  FRA
### Scientific Organizing Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martyn Caplin, London</td>
<td>GBR</td>
</tr>
<tr>
<td>Kjell Öberg, Uppsala</td>
<td>SWE</td>
</tr>
<tr>
<td>Massimo Falconi, Milan</td>
<td>ITA</td>
</tr>
<tr>
<td>Bertram Wiedenmann, Berlin</td>
<td>GER</td>
</tr>
<tr>
<td>Aurel Perren, Bern</td>
<td>SUI</td>
</tr>
<tr>
<td>Rocio García-Carbonero, Madrid</td>
<td>ESP</td>
</tr>
<tr>
<td>Reza Kianmanesh, Paris</td>
<td>FRA</td>
</tr>
<tr>
<td>Dermot O’Toole, Dublin</td>
<td>IRL</td>
</tr>
<tr>
<td>Marianne Pavel, Berlin</td>
<td>GER</td>
</tr>
</tbody>
</table>

### Conference Organization

**ENETS Office**
c/o Charité Universitätsmedizin Berlin  
Campus Virchow-Klinikum  
Hepatology and Gastroenterology  
Augustenburger Platz 1  
13353 Berlin, Germany

- **Tel.:** +49 30 450-553 096 (Program Information)  
- **Fax:** +49 30 450-553 942  
- **E-Mail:** enets.office@charite.de  
- **Website:** www.enets.org  
- **Conference E-Mail:** enets-annual-conference@charite.de  
- **General Conference Information:** www.enets.org/barcelona2015  
- **Hotel and Travel Arrangements:** hotels@enets.org

### Conference Venue

**El Centro de Convenciones Internacional de Barcelona (CCIB)**  
Plaça de Willy Brandt, 11-14  
08019 Barcelona  
t. +34 932 301 000  
f. +34 932 301 001  
www.ccib.es
Announcements/Deadlines 2015/2016

ENETS Summer School, Paris, France
(Submission deadlines to be announced, please check www.enets.org)

Second Call: CoE Excellence Academy Fellowship
Deadline for Application: 1 May 2015

The 13th ENETS Annual Conference will take place in Barcelona, Spain on 9-11 March 2016. Please note the following topics and dates:

- Early Bird Registration:
  1 September, 2015 – 30 November 2015

- ENETS Annual Conference Abstract Submission
  Deadline for Submission: 14 December 2015

- ENETS Annual Conference Travel Grant Application Submission
  Deadline for Application: 14 December 2015

Deadline for ENETS Grants and Awards Application is 5 January 2016 for the following:

- ENETS CoE Training Fellowship Grant
- ENETS CoE Young Investigator Grant
- Translational Research Grant, partially – industry sponsored -
- ENETS Hakan Ahlman Award